Zhang Xin, Dong Wei, Cheng Hongbo, Zhang Meixia, Kou Yongqiang, Guan Jian, Liu Qiaoyu, Gao Mingyue, Wang Xiuhua, Mao Shirui
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, China.
Asian J Pharm Sci. 2019 Sep;14(5):543-551. doi: 10.1016/j.ajps.2018.09.002. Epub 2018 Oct 12.
Improving peroral delivery efficiency is always a persistent goal for both small-molecule and macromolecular drug development. However, intestinal mucus barrier which greatly impedes drug-loaded nanoparticles penetration is commonly overlooked. Therefore, in this study, taking fluorescent labeled PLGA (poly (lactic-co-glycolic acid)) nanoparticles as a tool, the influence of anionic and nonionic surfactants on mucus penetration ability of nanoparticles and their mucus barrier regulating ability were studied. The movement of PLGA nanoparticles in mucus was tracked by multiple particles tracking method (MPT). Alteration of mucus properties by addition of surfactants was evaluated by rheology and morphology study. Rat intestinal villus penetration study was used to further evaluate penetration enhancement of nanoparticles. The effective diffusivities of the nanoparticles in surfactants pretreated mucus were increased by 2-3 times and the mucus barrier regulating capacity was also surfactant type dependent. Sodium dodecyl sulfate (SDS) increased the complex viscosity and viscoelastic properties of mucus, but poloxamer presented a decreased trend. Tween 80 maintained the rheological property of the mucus. With the mucus barrier regulated by surfactants, the penetration of nanoparticles in intestinal villus was obviously increased. In summary, the mucus penetration ability of nanoparticles could be enhanced by altering mucus microenvironment with surfactants. Tween 80 which largely retains the original mucus rheology and morphology properties may be a promising candidate for facilitating nanoparticle penetration through the mucus barrier with good safety profile.
提高口服给药效率一直是小分子和大分子药物研发的一个长期目标。然而,极大阻碍载药纳米颗粒渗透的肠道黏液屏障通常被忽视。因此,在本研究中,以荧光标记的聚乳酸-羟基乙酸共聚物(PLGA)纳米颗粒为工具,研究了阴离子和非离子表面活性剂对纳米颗粒黏液渗透能力及其黏液屏障调节能力的影响。采用多颗粒追踪法(MPT)追踪PLGA纳米颗粒在黏液中的运动。通过流变学和形态学研究评估添加表面活性剂后黏液性质的变化。采用大鼠肠绒毛渗透研究进一步评估纳米颗粒的渗透增强作用。纳米颗粒在经表面活性剂预处理的黏液中的有效扩散率提高了2至3倍,且黏液屏障调节能力也取决于表面活性剂类型。十二烷基硫酸钠(SDS)增加了黏液的复数黏度和黏弹性,但泊洛沙姆呈现下降趋势。吐温80维持了黏液的流变学性质。随着表面活性剂对黏液屏障的调节,纳米颗粒在肠绒毛中的渗透明显增加。总之,通过表面活性剂改变黏液微环境可增强纳米颗粒的黏液渗透能力。吐温80在很大程度上保留了原始黏液的流变学和形态学性质,可能是促进纳米颗粒安全地穿透黏液屏障的一个有前景的候选者。